The administration of standard doses of most antiretroviral drugs results in significant variations in plasma drug concentrations among different individuals, influencing antiviral activity as well as incidence of drug-related toxicities. The reasons for this large inter-individual variability in drug levels are multifactorial, and involve differences in metabolism related to gender, concomitant medications, drug compliance, underlying diseases and genetic factors. Pharmacogenetics is the discipline that analyses the genetic basis for the inter-individual variation in the body disposition of drugs. One of its main goals is to give grounds to individualized treatment. The majority of pharmacogenetic traits so far have involved drug metabolism. This is the case for the inherited variation in the pharmacokinetics and pharmacodynamics of drugs such as hydralazine or isoniazid, which is due to polymorphisms in the N-acetyltransferase-2 (NAT2) gene, which allows splitting the population into three categories: slow, intermediate, and fast metabolizers. Pharmacogenetic studies conducted so far with antiretroviral drugs have focussed on metabolizer enzymes at the liver and on transporter proteins on cell membranes. Herein, we review the most relevant metabolizer enzymes and protein transporters, along with the genetic polymorphisms, which seem to influence the pharmacokinetics of antiretroviral drugs, ultimately determining its efficacy and toxicity.
Introduction
Since the approval of the first antiretroviral drug, azidothymidine (AZT) in 1987, more than 20 drugs have been approved for the treatment of HIV infection, one the most devastating viral infections ever known in history. Although the combination of these drugs in triple regimens allows to completely suppress viral replication in many instances, not all patients respond equally well. Incomplete adherence to the medication and/or drug-related toxicities frequently leads to virological failure. Big efforts have been made in developing better tolerated drugs and simpler regimens, in an attempt to improve clinical outcomes. However, given the fact HIV infection remains uncurable and, therefore, warrants indefinite treatment, the genetic factors determining the inter-individual variability in drug efficacy and toxicity are now subject of intense research.
The cytochrome P450 enzymatic complex (CYP 450) is the main metabolizer involved in the liver clearance of non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI). Several polymorphisms at different CYP 450 isoenzymes are known to influence the metabolism of drugs in the liver, causing increased or decreased clearance. In addition, the activity of the P-glycoprotein (P-gp) cell membrane efflux pump influence the intracellular disposition of some antiretrovirals (particularly PI) and their tissue distribution. Polymorphisms at the genes encoding these protein transporters influences their expression and activity, what modulates the disposition of the transported drugs. Herein, we describe the most important genetic factors influencing the pharmacokinetics and pharmacodynamics of antiretroviral drugs, which ultimately determine its efficacy and toxicity.
Nucleoside reverse transcriptase inhibitors
The multidrug resistance proteins (MRP) are cell membrane proteins widely distributed in the body. They were originally identified as an alternative mechanism for transportmediated drug resistance. [1] [2] [3] Ten different members of the MRP family are currently known and at least seven of them, MRP 1-7, have been shown to confer resistance to cancer drugs.
Two polymorphisms at MRP-4 might have clinical relevance in HIV therapy. The T4131G change has been associated with higher intracellular concentrations of lamivudine (3TC)-triphosphate. On the other hand, the G3724A change seem to result in more elevated ZDV-triphosphate intracellular levels. 4 At this time it is unclear in what extent the variability in drug response seen upon exposure to these drugs could be explained by genetic variability at the MRP transporters.
Peripheral neuropathy is a common toxicity in patients treated with didanosine (ddI) and/or stavudine (d4T), which seems to result from mitochondrial injury. Hulgan et al. 5 studied the genetic factors that might influence the susceptibility to NRTI-associated peripheral neuropathy. They found that 21% of patients receiving ddI and/or d4T who developed peripheral neuropathy had a particular mitochondrial DNA genetic configuration, the so called haplogroup T, while only 4% of patients carrying this haplogroup did not develop neurologic symptoms along prolonged period of therapy.
Around 8% of patients starting abacavir (ABC) develop an hypersensitivity syndrome within the first 4-6 weeks of treatment, which is characterized by fever, rash, abdominal complaints, lethargy and acute respiratory symptoms. 6 Typically, the clinical picture worsen with continued administration of the drug and usually improve within 24 h following ABC discontinuation. However, rechallenges with ABC in subjects who had developed a prior hypersensitivity reaction may results in a severe recurrence of symptoms within hours, with increased risk of life-threatening hypotension and death. 7 The development of ABC hypersensitivity has been associated with an specific haplotype at the major histocompatibility complex (MHC), the most polymorphic of all human genes (Figure 1 ). The HLA-B locus is the most variable; more than 250 alleles have been identified so far. 8 The polymorphisms are mainly located in exons 2 and 3 encoding the extracellular domains a1 and a2, which are responsible for peptide binding and MHC restriction in lymphocytes.
Mallal and co-workers 9-11 recently described an association between the presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 haplotype with the susceptibility to ABC allergic reactions. The combination of these alleles yields positive and negative predictive values of 100 and 97%, respectively, supporting an important applicable clinical role for HLA typing before prescribing ABC. However, 83% of patients recruited in that study were Caucasians, so the high predictive value of HLA typing should be assessed in other ethnicities.
The cost-effectiveness of genotyping in routine clinical practice has not been proven yet. Recently, Hughes et al. 10 confirmed the association between HLA-B*5701 and the risk for ABC hipersensitivity, and concluded that HLA-B typing in patients considered for ABC therapy might be of clinical utility, although they acknowledge the potential limitations in subjects from other races than Caucasians.
Non-nucleoside reverse transcriptase inhibitors
Nevirapine (NVP) is metabolized in the liver by the CYP3A4 and CYP2B6 isoenzymes. 12 Among the many isoenzymes at the cytochrome P450, CYP3A4 is the most abundant, representing 30% of the total enzymatic complex, and one of the most variable. The encoding gene posses a widely range of inter-individual polymorphic expression. [13] [14] [15] About 60-90% of this variation is estimated to be due to genetic factors 16 and several polymorphisms have been described in the promoter of the CYP3A4 gene and in adjacent regions, the majority of them still not well characterized.
An association between the CYP2B6-516G4T substitution and NVP exposure has recently been shown. Patients homozygous for the variant allele presented 1.7-fold higher NVP plasma levels than those homozygous for the common allele. 17 The clinical implication of this observation remains unclear, but given that high NVP plasma levels have been associated to an increased risk of liver toxicity, 18, 19 individuals with the polymorphic allele might warrant a closer look for liver enzyme elevations during NVP treatment. HLA-DRB1*0101----Nevirapine Figure 1 The major histocompatibility complex (MHC). Major histocompatibility complex is a large cluster of genes found on the short arm of chromosome 6. The MHC is divided into the class I, II and III regions, each containing groups of genes with related functions. Some of the proteins coded by these genes influence the risk of antiretroviral toxicity.
The polymorphism 3435C4T at the MDR1 gene has been associated to low expression of the P-gp. In a recent study performed in patients from South Africa, this polymorphism was associated with a decreased risk of hepatotoxicity following initiation of NVP therapy. 20 The same observation was demonstrated in another report, in which the T allele at MDR1 was associated with a decreased risk of hepatoxicity in patients exposed to either EFV or NVP. 21 The P-gp might be involved in the transportation of NVP outside the cells. Thus, the reduction in the expression of P-gp might determine an accumulation of NVP and higher intracellular concentrations of the drug within the cells. Therefore, it is paradoxical to recognize a lower risk of hepatotoxicity in TT carriers, as higher NVP intracellular concentrations should be expected in them.
Another study 22 found a trend towards a decreased risk of hepatotoxicity taking NVP in carriers with the AA genotype at position 6986 in the CYP3A5 isoenzyme, while no implication for the CYP2B6-516 genotypes was found. These authors proposed that a genetic susceptibility to NVP hypersensitivity might be conferred by HLA markers located within the class II region of the MHC gene. Both the HLA-DRB1*0101 alelle and elevated CD4 þ T lymphocytes would determine this higher susceptibility.
Efavirenz (EFV) is widely used in the treatment of HIVinfected patients given its potency and convenience. 23, 24 However, EFV posses a narrow therapeutic range, as plasma drug levels above 4 mg/ml have been associated with more central nervous system (CNS) toxicity while the rate of virologic failure seems to be increased if the drug concentration falls below 1 mg/ml. 25 Variations in the hepatic metabolism of EFV are one of the main causes of important inter-individual variations in the plasma concentration of the drug. In this context, carriers of the A-G change at the CYP3A4*1B allele show a decrease in the activity of the encoded protein, and therefore show a decreased clearance of EFV in the liver. 26 EFV undergoes primary oxidative hydroxylation to 8-hydroxyefavirenz, which is its major metabolite (Figure 2 ), and to 7-hydroxyefavirenz, which is the minor metabolite. 27 This route is catalyzed by the 2B6 isoenzyme of the cytochrome P450 system (CYP2B6). 28 The CYP2B6 is coded by a polymorphic gene at chromosome 19, which spans a region of approximately 28 kb and contains nine exons. 29 Several polymorphisms conforming different alleles have been described and some of them have been tested to determine their influence on the expression of the CYP2B6 protein (Table 1) . 30 Alleles that carry polymorphisms 415A4G, 516G4T, 136A4G, 296G4A, 785A4G, 419G4A, and 1172T4A have all been associated with differences in the expression of the encoded proteins. [31] [32] [33] The relevance of CYP2B6 polymorphisms on EFV metabolism has been extensively analysed. Haas et al. assessed the impact of the 526G4T polymorphism on EFV clearance Figure 2 Metabolic pathway for Efavirenz. The low activity of CYP 2B6 due to genetic polymorphisms results in elevated EFV plasma levels, which are associated to higher incidence of central nervous system toxicity.
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S Rodríguez-Nóvoa et al in a study that included patients of several races. A significant reduction in the metabolism of EFV was noticed, along with increased EFV plasma levels in patients with the TT genotype at nucleotide 516 of the 2B6 gene. Accordingly, TT genotype patients treated with EFV showed a higher incidence of CNS adverse effects when compared with CC genotype carriers. 34 In our experience, EFV plasma levels are greatly influenced by CYP2B6 genotypes and, as a consequence, the rate of CNS toxicities is more frequent in patients carrying T/T or G/T genotypes as compared with G/G carriers ( Figure 3 ). 35, 36 In a Japanese study, patients homozygous for the CYP2B6*6 allele, which contains both 516G4T and 785A4G polymorphisms, showed significantly higher EFV plasma concentrations (25 mM) as compared with heterozygous or subjects without the allele *6 (10 and 8 mM, respectively). 37 In summary, there is no doubt that this polymorphism is associated with differences in EFV plasma levels and CNS toxicities in most populations, which suggest that prescription of lower EFV doses could be warranted in subjects harboring the T/T genotype in order to minimize side effects without compromising the efficacy of the drug.
Although efficacy and safety have generally been associated with EFV plasma levels, this has not been always the case. Rotger et al. 17 did not find any correlation between EFV toxicity and plasma drug levels, while the intracellular concentration of EFV and CYP2B6-516 genotype correlated with the incidence of CNS complaints. As expected, EFV plasma levels poorly predicted the concentration attained in the intracellular compartment. Similar criticisms have been reported by Haas et al., 38 who did not confirm an association between CYP2B6-516 genotypes and the risk of virological failure.
The long half-live of EFV explains that after discontinuing the drug, concentrations above the IC 50 can be detected as long as 21 days after treatment interruption. 39 Patients with the T/T genotype interrupting EFV therapy could select EFV resistance mutations more easily, due to the expected longer period for clearing EFV from plasma. If proven, differences in EFV metabolism should be considered when deciding the optimal time to stop EFV-containing regimens.
The P-gp is encoded by the multidrug resistance 1 gene (MDR1). 40 It transport xenobiotics from the cytoplasm to the extracellular space and, thus, provide a barrier for the accumulation of drugs inside the cells. 41, 42 The P-gp was firstly recognized in tumour cells as part of a mechanism of resistance to chemotherapy. More recently, P-gp and other transporters have been identified in many normal tissues as part of a mechanism to prevent the intracellular concentration of potential harmful substances. 42, 43 Efflux pumps activity influences the pharmacokinetics of antiretrovirals due to its strategic location: (i) in the apical or luminal surface of epithelial cells of the lower ). GG, common genotype; GT, heterozygote genotype; TT, homozygote polymorphic genotype. Pharmacogenetics of HIV therapy S Rodríguez-Nóvoa et al gastrointestinal tract, (ii) at the biliary membrane of canalicular hepatocytes, and (iii) in the brush-border membrane of the proximal tubules of the kidney. Therefore, P-gp substrates are actively excreted into the gastrointestinal lumen, bile and urine. 44, 45 Other sites of location of P-gp are the luminal surface of capillary endothelial cells, the blood-brain barrier, the placenta and lymphocytes (Figure 4 ). The expression of P-gp in different tissues may influence the disposition of antiretrovirals in them, modulating both their bioavailability and distribution into viral sanctuaries.
Several single nucleotide polymorphisms (SNPs) with potential consequences in the expression of the encoded protein have been identified in the MDR1 gene ( Figure 5 ). The C3435T change at exon 26 correlates with distinct intestinal P-gp levels and influences the uptake of orally administered P-gp substrates (i.e. digoxin). Taken this drug as an example, individuals homozygous for this polymorphism (T/T) show significantly lower duodenal P-gp expression and increased digoxin plasma levels. 46 The C3435T polymorphism is a silent change and thus it is unlikely that directly influences the expression of the MDR1 gene. However, it seems to be linked to one or more other unidentified changes in regions of the MDR1 gene that control its expression, such as the promoter or enhancer region, or in sequences that are important for mRNA processing. This explains why C3435T polymorphisms have been shown to influence plasma levels of some antiretrovirals. Although at this time it is unclear if EFV is a substrate for P-gp, Fellay et al. 47 found lower EFV plasma levels and better immune recovery in Caucasians who carried the T/T genotype. However, neither the differences in EFV pharmacokinetics nor in the rate of CD4 þ T cells gain were confirmed by others. 37 On the other hand, Haas et al. 38 have reported that polymorphism 3435C4T is associated with lack of EFV resistance. The antiviral activity of EFV is played inside the cells and therefore plasma levels might not correlated with the antiviral activity of the drug. Thus, at this time remains to be elucidated whether the C3435T polymorphism correlates with higher intracellular concentrations of EFV.
An association between the C/C genotype at the MDR1 gene codon 3435 and increased HDL-cholesterol levels has been reported in patients receiving EFV. 48 This observation is sustained by the fact that P-gp may be involved in the metabolic pathways of lipoproteins. 49 The overexpression of P-gp caused by EFV could increase HDL-cholesterol levels. This induction would be less intense in subjects with the T/T genotype, with the final result of lower HDL-cholesterol elevations in them. 
Protease inhibitors
Indinavir (IDV) and atazanavir (ATV) are widely used as part of HIV therapy. These drugs are associated with unconjugated hyperbilirubinemia, which runs asymptomatic and does not reflect liver injury, in 6-25 and 20-50% of treated patients, respectively. This adverse effect is a consequence of the competition of IDV and ATV with the physiologic binding of bilirubin to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), the enzyme that conjugates and clears the bilirubin from plasma ( Figure 6 ). Around 5-10% of the general population have decreased UGT1A1 activity, which is known as Gilbert syndrome, the main feature of which is asymptomatic hyperbilirubinemia. 51, 52 This genetic defect is caused by a TA insertion into the UGT1A1 promoter, yielding seven repetitions, instead of six, at the UGT1A1 promoter (TA 7 ).
IDV-induced hyperbilirubinemia manifests primarily in patients possessing the Gilbert's allele, while this toxicity is more frequent with ATV, even in the absence of the genetic defect. Patients with this extra dinucleotide (TA) that is present in allele *28 have an increase in bilirubin levels compared with those without the polymorphic allele. 54 A direct corelation between ATV plasma concentrations and bilirubin levels has also been noticed by others. 55 Most PI are subject to P-gp transportation. Polymorphisms at the MDR1 gene that affect P-gp activity may be the genetic underlying mechanism for significant inter-individual variations in PI plasma levels. Although the evidence supporting that ATV can be transported by P-gp is scarce, 56 we have observed lower ATV plasma levels in patients with genotype T/T receiving 400 mg of ATV, compared with those with the C/C genotype. 57 The identification of patients predisposed to develop ATV-related hyperbilirubinemia may have clinical relevance. Patients with genetic factors prone to develop this adverse event, as those described before, might benefit from drug level monitoring and dose adjustment.
Nelfinavir (NFV) plasma levels have been shown to be influenced by MDR1 polymorphisms. Fellay et al. described a correlation between NFV plasma levels and genotypes at position 3435. Lower concentrations were observed in patients carrying the T/T variant. Surprisingly, T/T carriers were found to show higher CD4T cell gains under NFV therapy, despite having and unfavourable pharmaockinetic profile. 47 This observation, however, has not been confirmed by others. In a recent study, Saitoh et al. showed that children carrying the 3435 polymorphism in heterozygosis (C/T) had higher NFV plasma levels than children with the C/C or T/T genotypes. In the same study, the percentage of virological responders at week 8 was higher in C/T genotype carriers, who were children with greater NFV plasma levels. 58 Thus, at this time, it is unclear if the presence of the T allele is associated with higher or lower NFV plasma levels. Differences between the two studies (age of the study population, concomitant medications which could influence P-gp activity, etc.) might explain their discordant results.
Zhu et al. 59 measured the intracellular concentrations of NFV in lymphoblastoid cell lines and examined the genotypes at position 3435. They found much higher NFV concentrations in the T/T genotype than in C/C or C/T genotypes. This was confirmed in a recent study in which patients with the T/T genotype had higher intracellular exposure than those with C/T or T/T genotypes. 60 These data support the previous observation of a better immune recovery under NFV treatment in T/T carriers.
IDV is mainly metabolized in the liver by the isoenzyme CYP3A5, which shows high genetic variability. 61 The allele *3 is one of the most well known at CYP3A5; its frequency varies among different races. [62] [63] [64] [65] A guanine at position 6983 in this allele creates a cryptic splice site at intron 3, which leads to aberrant splicing of most transcripts and very low CYP3A5 protein expression. 62 Thus, the presence of this variant has been associated with low or null expression of the CYP3A5 protein and, as a consequence, with a lower clearance of IDV. 66 The result is that individuals with this polymorphism tend to show higher IDV plasma levels and suffer more frequently from kidney stones under IDV therapy.
The MRP are also well established transporters of some PI and NRTI. 67, 68 In vitro studies have reported decreased intracellular accumulation of ritonavir (RTV) and saquinavir (SQV) in cell lines overexpressing either P-gp or MRPs. 69 Accordingly, Anderson et al. 4 found a trend for a faster IDV clearance in subjects with a polymorphism in the MRP-2 promoter (C-24T).
As PI are metabolized by different isoenzymes of the cytochrome P450 and they are also substrates of the P-gp, genetic changes modulating their disposition may affect drug metabolism in the liver and tissue distribution, with complex results which ultimately influence their efficacy and safety profile.
Pharmacogenetics and toxicity of antiretroviral drugs
Lipodystrophy and the metabolic syndrome are frequent complications of antiretroviral therapy. Independent risk factors for peripheral fat wasting (lipoatrophy) include white race and prolonged exposure to nucleoside analogues, particularly stavudine (d4T). 70 The use of RTV and RTVboosted PI regimens are the most significant predictors of hypercholesterolemia and hypertriglyceridemia, whereas the use of d4T, ZDV, ddI and PI are mainly associated with fat tissue redistribution. However, metabolic abnormalities do not occur in all patients, despite comparable demographics, similar drug exposure, as well as immunologic and virologic treatment response. Polymorphisms in genes involved in lipoprotein and adipocyte metabolism could explain this discrepancy.
Allelic variants in apolipoprotein C-III (APOC3) and apolipoprotein E (APOE) genes seem to contribute significantly to elevations in plasma triglyceride levels, to a degree comparable to factors such as age or the use of RTVcontaining regimens. Polymorphisms in the APOC3 gene that have been associated with a higher risk of developing hyperlipidemia are À482C4T, À455T4C and 3238C4G. 71, 72 In the presence of RTV, individuals with unfavourable genotypes in APOC3, in particular in association with APOE variants APOE-e2 and APOE-e4, are at risk of extreme hypertriglyceridemia.
In contrast with the prior reports, Foulkes et al. have recently claimed that there is no association between any of the SNPs at APOC3 (À482C4T, À455T4C, 3238 C4G, intron 1 and Gly34Gly) and triglyceride levels, HDLcholesterol or LDL-cholesterol, in Caucasian or African patients. 72, 73 However, when the analyses was restricted to Hispanics, the associations were recognised for the effect of PI on triglycerides.
Multiple genetic factors seem to modulate the risk of lipodystrophy in HIV-positive patients taking antiretroviral drugs. The influence of TNFa polymorphisms on its development is currently subject to intense study. Preliminary data suggest that polymorphism À238G4A may favor a more rapid development of lipoatrophy. [74] [75] [76] Finally, HIV-positive patients may develop different pancreatic disorders as a result of opportunistic infections, antiretrovirals or other drugs used to treat HIV-related complications. Mild to moderate asymptomatic elevations of serum amylase or lipase are common. Polymorphisms at the serin-protease inhibitor Kazal-1 (SPINK-1), which encodes a trypsin inhibitor in the cytoplasm of pancreatic acinar cells, and the cystic fibrosis transmembrane conductance regulator (CFTR), have both been associated with the risk of pancreatitis in HIV-infected patients undergoing antiretroviral therapy. 77 
Pharmacogenetics and efficacy of antiretroviral drugs
The 3435C4T polymorphism at the MDR-1 gene has been examined in order to elucidate its influence on HIV disease progression and response to therapy. There is no concordance between the different studies. While some have described a relationship between the CC genotype and earlier virological failure, others have not found any difference in host susceptibility to HIV disease progression or in the CD4 recovery following initiation of antiretroviral therapy. [78] [79] [80] [81] Saitoh et al. have recently described a more rapid decline in plasma HIV-RNA in response to therapy in children with the C/T genotype. 58 Anecdotal reports have described an effect of the expression of P-gp on inhibition of virus production. Lee et al. demonstrated that P-gp expression may affect HIV infectivity. These authors observed a reduction in virus production when P-gp was overexpressed at the surface of a continuous CD4 þ human T-leukemic cell line infected with HIV-1. 55 This reduction in viral infectivity occurred both during the fusion of viral and plasma membranes and at subsequent steps in the HIV-1 cycle. However, Ifergan et al. 79 compared infected and non-infected Caucasian individuals highly exposed to HIV and they observed no differences in the distribution of P-gp genotypes between both groups, suggesting that P-gp expression does not play a major role in the susceptibility to HIV infection.
Future perspectives
Human genetic variation is responsible for a large part of the inter-individual responses to antiretroviral drugs. The application of pharmacogenetics into clinical practice is often difficult since in most instances no strong and uniform correlation exist between single polymorphisms and plasma drug levels, and between those and antiviral activity and/or drug-related side effects. Each antiretroviral drug may interact with numerous targets, such as carrier proteins, transporters or metabolizing enzymes. Nuclear receptors are another factor of genetic variability. These proteins are known to regulate the transcription of cytochrome P450 isoenzymes and certain protein transporters. CAR splicing variants with deletions of several exons show different levels of expression. 84 These variants possess differences in the binding to CYP2B6 regulatory elements. At this time it is unclear the effect of variations in this protein on intracellular or plasma levels of antiretrovirals. However, variability in nuclear receptors deserves future investigation, given their probable influence on pharmacokinetics and pharmacodynamics of antiretroviral drugs. Table 2 summarizes the main genetic factors influencing the pharmacokinetics of different antiretrovirals. In summary, pharmacogenetics seem to be a promising discipline, which may help to improve the use antiretroviral drugs, maximizing its efficacy and reducing its toxicity. However, the multiplicity of the genes involved and the complex interactions among them and the corresponding expressed molecules obliges to accumulate more information before claiming that time has arrived to implement it in daily clinical practice.
